Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
Starling Oncology, a value-based community oncology group listed on NASDAQ as STLN, announced solid financial results for Q2 2026 with a 34.6% revenue increase year-over-year to $161.3 million and adjusted EBITDA turning positive at $229 thousand. The company raised its full-year 2026 guidance for revenue to $650-$670 million and gross profit to $1…